Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Equity Ratio (2016 - 2025)

Altimmune (ALT) has disclosed Equity Ratio for 16 consecutive years, with 0.85 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 5.81% to 0.85 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.85, a 5.81% decrease, with the full-year FY2024 number at 0.89, down 3.78% from a year prior.
  • Equity Ratio was 0.85 for Q3 2025 at Altimmune, roughly flat from 0.85 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.94 in Q2 2021 to a low of 0.85 in Q2 2025.
  • A 5-year average of 0.9 and a median of 0.9 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: increased 20.94% in 2021, then dropped 5.81% in 2025.
  • Altimmune's Equity Ratio stood at 0.91 in 2021, then decreased by 1.58% to 0.9 in 2022, then rose by 2.91% to 0.92 in 2023, then fell by 3.78% to 0.89 in 2024, then decreased by 4.17% to 0.85 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Equity Ratio are 0.85 (Q3 2025), 0.85 (Q2 2025), and 0.9 (Q1 2025).